RUNX1 has a critical role in normal and malignant hematopoiesis and megakaryocyte development.18 The loss of RUNX1 leads to downregulation of p19 and accelerates the development of MLL-ENL leukemia in mice because of the enhanced proliferation of leukemic cells.19 Our study demonstrates that the identification of novel players that potentially modulate leukemia cell proliferation as well as restore the intrinsic differentiation machinery may be helpful for the development of new therapeutic methods. Here, KMT2A is linked to leukemia.